AxS007 / Nanocarry Therapeutics - LARVOL DELTA

Nanocarry Therapeutics’ Brain Penetrating Nanoplatform Selected by the NCI Nanotechnology Characterization Laboratory for its Preclinical Characterization Program (GlobeNewswire) - "Nanocarry Therapeutics...announced the selection of its lead product, AxS007, by the U.S. National Cancer Institute’s (NCI’s) Nanotechnology Characterization Laboratory (NCL) for comprehensive preclinical characterization....Through this collaboration, the NCL will conduct detailed preclinical evaluations of AxS007. These studies will support the advancement of AxS007 towards filing an Investigational New Drug (IND) application with the FDA and facilitate future clinical development."

Preclinical • Breast Cancer • Oncology • Solid Tumor